• Read the Report
  • Contact Us
Menu
  • Background
    • HIV and the Law
    • Commission Overview
    • Commissioners
    • Technical Advisory Group
  • Dialogues
    • Global Dialogue 2018
      • 2018 Supplement
      • Global Dialogue 2018 Videos
    • Global Dialogue 2012
      • Video
      • Photo Gallery
      • Speeches
    • Regional Dialogues
      • Asia-Pacific Regional Dialogue
      • Caribbean
      • Eastern Europe and Central Asia
      • Latin America
      • Africa
      • Middle East and North Africa
      • High Income Countries
      • Civil Society Participation
      • Submissions to the Regional Dialogues
  • Implementation
    • Programmes
      • Being LGBTI in Asia
      • Challenging stigma and discrimination in the Caribbean
      • Improving SRHR for young key populations in Southern Africa
      • Multi-Country Western Pacific Integrated HIV/TB Project
      • Promoting a rights-based response to HIV in Africa
      • Removing legal barriers in Africa
      • South Asia Global Fund HIV Programme
      • UHC Legal Solutions Network
    • Follow Up
      • Follow Up Stories
      • Legal Environment Assessments
      • Leave No One Behind: Lessons from the Global Commission on HIV and the Law for Agenda 2030
  • Resources
    • International Guidelines on Human Rights & Drug Policy
    • eLibrary
      • Capacity Development Toolkits
      • Fact Sheets
      • Legal Environment Assessments, Reviews and Audits
      • National Dialogue Reports
      • Policy and Issue Briefs
      • Research, Discussion Papers and Reports
    • Report Resources
      • Read the Report
      • 2018 Supplement
      • Working Papers
      • Submissions
      • Presentations
      • Articles and Speeches from Commissioners
      • Selected Bibliographies
    • Regional Dialogue Resources
      • Asia-Pacific
      • Caribbean
      • Latin America
      • Eastern Europe and Central Asia
      • Africa
      • High Income Countries
  • News
    • News Articles
    • Press Releases
    • Newsletter Archives
  • Past Events
Follow Up Stories

Focusing on prices of HIV medicines in middle-income countries | Tenu Avafia & Katie Kirk

By katemcqdev

27/06/2013

Focusing on prices of HIV medicines in middle-income countries | Tenu Avafia & Katie Kirk

Published on Thursday, 27 June 2013 11:33

PHOTO: UNDP

A key determinant of middle-income countries meeting their health-related Millennium Development Goals (MDGs) will be their ability to sustain and expand access to treatment for HIV and its co-infections, like TB and Hepatitis C.

By 2020, the majority of people living with HIV will be living in middle-income countries, such as South Africa, Brazil, Russia, Ecuador and Thailand. Yet at the same time as new, more effective medicines to treat HIV emerge, many of these countries, based on their average income levels, are increasingly being left out of special arrangements offered by pharmaceutical companies to low-income countries, such as price discounts or voluntary licenses to use their patents.

For instance, in 2011, using Global Fund grants, HIV medicine Darunavir was offered to Sub-Saharan African countries at US $1,095 per patient per year. Meanwhile, Nicaragua and Moldova (middle-income countries) had to buy that same medicine at $7,424 and $9,188 respectively.

This pricing challenge will test the 2011 commitment made by UN Member States, at a UN High-level Meeting on AIDS , to place 15 million people in need on antiretroviral treatment by 2015.

Eighteen middle-income countries and stakeholders met in Brasilia in June to confront these challenges. Whether discussing intellectual property, drug registration, procurement or supply-chain management, a critical –take-away was that increasing collaboration between countries in the global South represents a key opportunity to meet common objectives.

So individually or in collaboration, how can middle-income countries confront the challenge of sustaining treatment? Of course, the experiences vary between countries, but in general, middle-income countries want to foster increased competition among medicine suppliers to reduce the cost of treatment by:
  • Incorporating flexibilities found in the Agreement on Trade-Related Aspects of Intellectual Property Protection (TRIPS) into national legislation, and using them to increase competition among drug suppliers
  • Developing effective regulatory frameworks for evaluating drugs’ safety and efficacy
  • Promoting local pharmaceutical manufacturing
  • Increasing transparency during procurement of medicines
During the meeting, UNDP made a presentation on competition law and policy’s potential as a tool to increase access to treatment. To continue to support efforts to increase access to these life-saving treatments, UNDP will be launching a guide on competition law, intellectual property and access to medicines in the next few months.

Talk to us: What can middle-income countries do to make sure HIV medicine is affordable and accessible to their affected populations?  

Source: UNDP

Share this:

  • Twitter
  • Facebook

Recent Posts

  • UNAIDS update: COVID-19 should not be a reason to delay 2030 deadline to end AIDS as a public health threat
  • 2020 Global HIV Policy Report: Policy Barriers to HIV Progress
  • UNAIDS hails new results showing that long-acting injectable medicines are highly effective in preventing HIV among women
  • UNDP and Supreme Court of Republic of Tajikistan hold international online Judges’ Forum on HIV, Human Rights and the Law
  • Press Release – New HIV Policy Lab uses law and policy data in the HIV response

© 2017 [blog-link], All Rights Reserved.